Genmab Total Liabilities 2019-2024 | GMAB

Genmab total liabilities for the quarter ending June 30, 2024 were $1.104B, a 134.43% increase year-over-year.

  • Genmab total liabilities for 2023 were $0.534B, a 32.98% increase from 2022.
  • Genmab total liabilities for 2022 were $0.402B, a 3.86% increase from 2021.
  • Genmab total liabilities for 2021 were $0.387B, a 24.86% increase from 2020.

Genmab Total Liabilities 2019-2024 | GMAB

  • Genmab total liabilities for 2023 were $0.534B, a 32.98% increase from 2022.
  • Genmab total liabilities for 2022 were $0.402B, a 3.86% increase from 2021.
  • Genmab total liabilities for 2021 were $0.387B, a 24.86% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$173B
Vertex Pharmaceuticals (VRTX)$127.1B
Gilead Sciences (GILD)$114.2B
Bristol Myers Squibb (BMY)$112.1B
CSL (CSLLY)$91B
Regeneron Pharmaceuticals (REGN)$89.7B
GSK (GSK)$74.4B
Argenex SE (ARGX)$35.2B
Alnylam Pharmaceuticals (ALNY)$35.2B
Biogen (BIIB)$25.4B
BioNTech SE (BNTX)$25.4B
Illumina (ILMN)$24.2B
Moderna (MRNA)$19.9B
BeiGene (BGNE)$19.7B
Incyte (INCY)$15.6B
Insmed (INSM)$13B
Vaxcyte (PCVX)$13B
BioMarin Pharmaceutical (BMRN)$12.6B
Sarepta Therapeutics (SRPT)$12.2B
Bio-Techne Corp (TECH)$12B
Exelixis (EXEL)$10.1B
Exact Sciences (EXAS)$10.1B
QIAGEN (QGEN)$10B
Revolution Medicines (RVMD)$9.9B
Intra-Cellular Therapies (ITCI)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.7B
Repligen (RGEN)$8.2B
Ascendis Pharma (ASND)$7.8B
Halozyme Therapeutics (HALO)$7.7B